The Anti-infectives Knowledge Network – Invasive Fungal Infections (AIKN-IFI), an initiative by Astellas Pharma EMEA, shares the expertise and experience of a number of thought leaders in the disease therapy area of Anti-infectives.
The Anti-infectives Knowledge Network – Clostridium difficile Infections (AIKN-CDI), an initiative by Astellas Pharma EMEA Ltd., shares the expertise and experience of a number of thought leaders in the disease therapy area of Anti-infectives.
Most recent updated with content from ID Week 2014, these reports detail the national estimates of CDI incidence in the USA, how to predict the risk of CDI and the burden that recurrent CDI brings to healthcare settings.
Would you trust a doctor to decide if you are an appropriate subject for assisted dying? I wouldn't, neither should you, and my colleagues who are not fortunate enough to be retired will be crazy if they allow themselves to be dragged into the process. Proponents of legislative change should man up and face the implications of their proposals, without hiding behind the medical profession.
Transfer of donor immunity after allo-HSCT is limited, requiring re-vaccination after HSCT. The CDC 2009 guidelines introduced earlier vaccination post-HSCT with a uniform vaccination strategy. This ...
These evidence-based guidelines expand and adapt previous guidance (Tomblyn et al, 2009; Andrews et..
... al, 2011). While specifically focusing on allogeneic haemopoietic stem cell transplantation (HSCT), they are relevant to other areas of haematological oncology where there is an increased risk of cytomegalovirus (CMV) infection, such as haematological cancers where intense anti-T-cell therapy has been deployed (O’Brien et al, 2006).
Fungal diseases still play a major role in morbidity and mortality in patients with haematological..
... malignancies, including those undergoing haematopoietic stem cell transplantation. Although Aspergillus and other filamentous fungal diseases remain a major concern, Candida infections are still a major cause of mortality. This part of the ESCMID guidelines focuses on this patient population and reviews pertaining to prophylaxis, empirical/pre-emptive and targeted therapy of Candida diseases. AntiCandida prophylaxis is only recommended for patients receiving allogeneic stem cell transplantation.
The aim of this study is to investigate the effectiveness of the program in patients after renal transplantation using a randomized controlled trial design. Physical, behavioural, and clinical outcomes will be measured at baseline before randomization then 8 and 12 months later.